NCT03182738

Brief Summary

The purpose of this study is to use technology to improve symptom status and ultimately improve patient centered outcomes in people living with HIV/AIDS (PLWHA). The primary purpose of the intervention (VIP-HANA) is to improve symptom status. The investigators hypothesize that VIP-HANA will improve symptom frequency and intensity.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 16, 2016

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

May 11, 2017

Completed
29 days until next milestone

First Posted

Study publicly available on registry

June 9, 2017

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 3, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2019

Completed
7 months until next milestone

Results Posted

Study results publicly available

December 13, 2019

Completed
Last Updated

December 13, 2019

Status Verified

November 1, 2019

Enrollment Period

2.4 years

First QC Date

May 11, 2017

Results QC Date

October 27, 2019

Last Update Submit

November 21, 2019

Conditions

Keywords

HIV/AIDS Health Management AppHIV/AIDS symptoms

Outcome Measures

Primary Outcomes (1)

  • Symptom Burden Score

    The Symptom Burden Score is an expanded version of the 20-item HIV symptom index. The score is calculated for the 28 most common symptoms in persons living with HIV. Each symptom is given a score ranging from 0 to 4 with the scores indicating the following: 0 (not experienced) , 1 (It doesn't bother me), 2 (It bothers me a little), 3 (It bothers me), or 4 (It bothers me a lot). The higher the score (closer to 4), the greater the symptom burden (worse outcome).

    Baseline, 3 months and 6 months; period 1 = 1-6 weeks (baseline), period 2 = 6-18 weeks (3 months), period 3 = >18 weeks (6 months)

Secondary Outcomes (1)

  • Score on Patient-Reported Outcomes Measurement Information System® (PROMIS)-29

    Baseline, 3 months, and 6 months

Other Outcomes (4)

  • Change in Score on SF-12

    3 months and 6 months

  • Score on Engagement With Health Care Provider Scale

    Baseline, 3 months, and 6 months

  • Score of the VAS

    Baseline, 3 months, and 6 months

  • +1 more other outcomes

Study Arms (2)

Intervention

EXPERIMENTAL

VIP app that delivers HIV-related symptom strategies

Behavioral: VIP app that delivers HIV-related symptom strategies.

Control

SHAM COMPARATOR

VIP app without HIV-related symptom strategies

Behavioral: VIP app without HIV-related symptom strategies.

Interventions

The control group will receive the VIP app without HIV-related symptom strategies

Control

The Intervention group will receive the VIP app that delivers HIV-related symptom strategies

Intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • HIV+
  • Age 18 or over
  • Able to read and respond in English
  • Reside within the US
  • Willing to participate in an online survey.

You may not qualify if:

  • HIV-negative
  • under age 18
  • Unwilling to provide key data (i.e., age, information about symptoms) on the online survey.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Columbia University School for Nursing

New York, New York, 10032, United States

Location

Related Publications (2)

  • Gordian-Arroyo A, Reame N, Gutierrez J, Liu J, Ganzhorn S, Igwe KC, Laing K, Schnall R. Do correlates of white matter features differ between older men and women living with human immunodeficiency virus? Menopause. 2023 Feb 1;30(2):149-155. doi: 10.1097/GME.0000000000002102. Epub 2022 Nov 20.

  • Cho H, Porras T, Flynn G, Schnall R. Usability of a Consumer Health Informatics Tool Following Completion of a Clinical Trial: Focus Group Study. J Med Internet Res. 2020 Jun 15;22(6):e17708. doi: 10.2196/17708.

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

HIV InfectionsBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesSlow Virus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Results Point of Contact

Title
Dr. Rebecca Schnall
Organization
Columbia University School of Nursing

Study Officials

  • Rebecca Schnall, PhD

    Columbia University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Nursing

Study Record Dates

First Submitted

May 11, 2017

First Posted

June 9, 2017

Study Start

November 16, 2016

Primary Completion

April 3, 2019

Study Completion

May 31, 2019

Last Updated

December 13, 2019

Results First Posted

December 13, 2019

Record last verified: 2019-11

Data Sharing

IPD Sharing
Will not share

Locations